Abstract

ObjectivePatients treated with antipsychotic drugs often receive concomitant psychotropic compounds. Few studies address this issue from a lifetime perspective. Here, an analysis is presented of the prescription pattern of such concomitant medication from the first contact with psychiatry until the last written note in the case history documents, in patients with a diagnosis of psychotic illness.MethodsA retrospective descriptive analysis of all case history data of 66 patients diagnosed with schizophrenia or schizophrenia-like psychotic disorders.ResultsBenzodiazepines and benzodiazepine-related anxiolytic drugs had been prescribed to 95% of the patients, other anxiolytics, sedatives or hypnotic drugs to 61%, anti-parkinsonism drugs to 86%, and antidepressants to 56% of the patients. However, lifetime doses were small and most of the time patients had no concomitant medication. The prescribed lifetime dose of anti-parkinsonism drugs was associated with that of prescribed first-generation but not second-generation antipsychotics.ConclusionsMost psychosis patients are sometimes treated with concomitant drugs but mainly over short periods. Lifetime concomitant add-on medication at the individual patient level is variable and complex but not extensive. Copyright © 2011 John Wiley & Sons, Ltd.

Highlights

  • Antipsychotic drugs are regarded as a cornerstone in the treatment of schizophrenia and related psychoses, it is well known that a number of other drugs are used in these patient categories

  • Concomitant drugs prescribed to psychotic patients Prescription records of concomitant medication that fell into nine broad categories were analysed in this study

  • Benzodiazepines and benzodiazepine‐related anxiolytic drugs had been prescribed to 95% (N = 63) of the patients, other anxiolytics, sedatives or hypnotic drugs to 61% (N = 40), anti‐parkinsonism drugs to 86% (N = 57) and antidepressants to 56% (N = 37) of the patients

Read more

Summary

Introduction

Antipsychotic drugs are regarded as a cornerstone in the treatment of schizophrenia and related psychoses, it is well known that a number of other drugs are used in these patient categories. Concomitant medication, e.g. benzodiazepines, antidepressants, anti‐parkinsonism drugs, mood stabilisers and beta‐adrenergic blockers have received attention as add‐on therapies or alternative drugs in the treatment of schizophrenia to manage certain specific as well as treatment resistant symptoms. This add‐on medication give rise to potential disadvantages, such as pharmacokinetic and pharmacodynamic interactions, worsening of certain symptoms or risk for being continued without a need (Meyer, 2007). A review spanning studies performed during a period of 43 years could confirm some effectiveness of benzodiazepines only for short term sedation of acutely ill patients diagnosed with schizophrenia (Volz et al, 2007).

Methods
Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.